RxDoctor Payments DataLook up a doctor →

Jennifer Diamond, MD

Hematology & Oncology · Aurora, CONPI 1912053513

Payments from drug & device makers

$7,086,184in general payments, 2019–2025

Across 1,242 payments — averaging $5705.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$1.1M
  • AstraZeneca$947K
  • Merck$919K
  • Deciphera Pharmaceuticals Inc.$696K
  • Astellas Pharma Global Development$605K
  • E.r. Squibb & Sons, L.L.C.$569K
  • plus $2.3M from 16 others

What the payments were for

  • Consulting fees$7,56470%
  • Speaking & faculty fees$1,92518%
  • Travel & lodging$8448%
  • Food & beverage$3723%
  • Education$360%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,086,184 in reported general payments places this provider in the 90th percentile of 169 hematology & oncology providers in Colorado.

See all hematology & oncology providers in Colorado

Medicare billing

Part B allowed, 2024
$30,679
Medicare patients
72
Services billed
232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib36$518,553
KisqaliRibociclib Succinate36$418,710
VerzenioAbemaciclib14$192,220
EliquisApixaban17$17,129
Anastrozole122$2,368
Exemestane11$2,121
Letrozole36$804
Tamoxifen Citrate34$762
LoperamideLoperamide Hcl13$209
Dexamethasone17$152
Prochlorperazine Maleate17$140
Duloxetine Hcl13$113
Ondansetron Hcl17$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$399,738$535,68253 claims
NovartisKisqali$75$418,71036 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 169 hematology & oncology providers in Colorado.

Other hematology & oncology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →